Key result
Cardiogenic shock trials struggle to produce high-quality evidence due to acute illness and poor clinical equipoise.
Why the study?
Patients with cardiogenic shock due to STEMI are acutely ill and clinicians may lack equipoise, presenting challenges to developing high-quality evidence to guide practice.
This review outlines the methodological and ethical challenges of conducting clinical trials in patients with cardiogenic shock and offers potential solutions.
Answers are grounded in this paper and cite their sources.
Underscores barriers to rigorous cardiogenic shock trials; leaves open feasible designs and ethical solutions for future studies.
Cardiogenic shock due to ST-segment elevation myocardial infarction is associated with high morbidity and mortality. Patients in shock are acutely ill, and clinicians may lack equipoise, thus presenting a challenge to developing high-quality evidence to guide practice. This review will summarize these challenges and offer possible solutions.
No takes yet. Share an insight, caveat, or question.
Sunil V. Rao (2022) studied this question. Clinical trials for cardiogenic shock face significant challenges in generating high-quality evidence due to acute patient illness and a lack of clinical equipoise.
Synapse has enriched 10 related papers. Consider them for comparative context: